The combination of the aliphatic diamine AA0029 in ADAD vaccination system with a recombinant fatty acid binding protein could be a good alternative for the animal schistosomiasis control

Vicente, Belén; López‐Abán, Julio; Rojas-Caraballo, José; Olmo, Esther del; Fernández‐Soto, Pedro; Ramajo-Martín, Vicente; Muro, Antonio

doi:10.1016/j.exppara.2015.04.022

Cited by 1 publication

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed a high protection in terms of worm recovery, eggs trapped in the tissues and hepatic damage in mice vaccinated with the native nFh12 and the E. coli recombinant rFh15. These results are close to those obtained by vaccination against S. bovis with both antigens formulated in ADAD vaccination system with PAL as well as AA0029 [ 22 , 23 ]. Our results are also comparable to those shown using the FABP Sm14 obtained from S. mansoni in experimental models [ 16 ] or using the F. gigantica 14.6 kDa molecule [ 24 ].…”

Section: Discussionsupporting

confidence: 86%

“…Also, vaccinated animals generated high levels in both IgG and IgG1 against SoSmAWA 8 weeks post-challenge, but there was significant production of IgG2a only using the natural immunomodulator PAL. This effect has been observed in previous studies related to the use of PAL in vaccination against F. hepatica and S. bovis and its association with protection and downregulation of the dominant Th2 established in schistosomes or F. hepatica infections [ 22 , 23 , 41 , 42 ]. An appropriate adjuvant system able to induce an adequate immune response is recognised as an important tool for developing vaccines.…”

Section: Discussionsupporting

confidence: 72%

“…A significant effort has been focused on schistosomiasis vaccine development because of its potential ability to control or eradicate the disease. FABP from F. hepatica have demonstrated a valuable cross-protection against S. bovis in experimental models [ 20 – 23 ]; similar effects were reported for FABP of 14.6 kDa from F. gigantica [ 24 ]. Also, the S. mansoni FABP Sm14 have reached Phase I studies [ 19 ].…”

Section: Discussionmentioning

confidence: 66%

“…The native nFh12 and the recombinant rFh15 FABP from F. hepatica have shown protection in terms of reduction of worm burden and liver lesions using Freund’s adjuvant in C57/BL6 mice against S. bovis infection [ 20 , 21 ]. Moreover, large parasite burden reduction, liver lesion amelioration and anti-fecundity effects were observed in BALB/c mice and golden hamsters vaccinated with the rFh15 using the ADAD (adjuvant adaptation) vaccination system against S. bovis [ 22 , 23 ]. Furthermore, a FABP of 14.6 kDa purified from Fasciola gigantica has proved reductions in parasite counts and liver lesions against S. mansoni infection in CD1 mice [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

“…The synthetic diamine AA0029 inhibits lymphoproliferation, modulates delayed-type hypersensivity in a T. spiralis model, modifies the ratios of CD8+, CD4+ and MHC Class II cells and increases nitric oxide production in LPS pre-stimulated rat alveolar macrophages [ 29 ]. Experiments using 14-3-3 protein from S. bovis , and FABP from F. hepatica formulated in ADAD system have yielded high protection in terms of parasite burden and liver damage [ 22 , 23 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundSchistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection.MethodsBALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied.ResultsVaccination with nFh12 induced significant reductions in worm burden (83 %), eggs in tissues (82–92 %) and hepatic lesions (85 %) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56–64 %), eggs in the liver (21–61 %), eggs in the gut (30–77 %) and hepatic damage (67–69 %) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60 %, respectively), and hepatic lesions (45 %). We observed a significant rise in TNFα, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFNγ and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15.ConclusionsHigher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins.Electronic supplementary materialThe online version of this article (doi:10.1186/s13071-016-1500-y) contains supplementary material, which is available to authorized users.

show abstract